Actinium Pharmaceuticals Inc. (AMEX:ATNM) went up by 8.37% from its latest closing price compared to the recent 1-year high of $13.18. The company’s stock price has collected 33.68% of gains in the last five trading sessions. Press Release reported 14 hours ago that Actinium Announces Multiple Senior Leadership Appointments Including Chief Business and Commercial Officer, New Chief Medical Officer and Vice President, Patent and Legal Counsel
Is It Worth Investing in Actinium Pharmaceuticals Inc. (AMEX :ATNM) Right Now?
Plus, the 36-month beta value for ATNM is at 0.97. Opinions of the stock are interesting as 5 analysts out of 5 who provided ratings for Actinium Pharmaceuticals Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $32.50. ATNM currently public float of 19.85M and currently shorts hold a 4.20% ratio of that float. Today, the average trading volume of ATNM was 200.67K shares.
ATNM’s Market Performance
ATNM stocks went up by 33.68% for the week, with a monthly jump of 44.73% and a quarterly performance of 13.90%, while its annual performance rate touched 0.22%. The volatility ratio for the week stands at 10.68% while the volatility levels for the past 30 days are set at 6.54% for Actinium Pharmaceuticals Inc.. The simple moving average for the period of the last 20 days is 37.03% for ATNM stocks with a simple moving average of 11.96% for the last 200 days.
Analysts’ Opinion of ATNM
Many brokerage firms have already submitted their reports for ATNM stocks, with Alliance Global Partners repeating the rating for ATNM by listing it as a “Buy.” The predicted price for ATNM in the upcoming period, according to Alliance Global Partners is $25 based on the research report published on November 05th of the previous year 2020.
B. Riley FBR Inc., on the other hand, stated in their research note that they expect to see ATNM reach a price target of $2.75. The rating they have provided for ATNM stocks is “Buy” according to the report published on December 06th, 2017.
ROTH Capital gave a rating of “Buy” to ATNM, setting the target price at $6 in the report published on October 23rd of the previous year.
ATNM Trading at 34.81% from the 50-Day Moving Average
After a stumble in the market that brought ATNM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -32.26% of loss for the given period.
Volatility was left at 6.54%, however, over the last 30 days, the volatility rate increased by 10.68%, as shares surge +45.92% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +31.71% upper at present.
During the last 5 trading sessions, ATNM rose by +33.68%, which changed the moving average for the period of 200-days by -18.07% in comparison to the 20-day moving average, which settled at $6.66. In addition, Actinium Pharmaceuticals Inc. saw 14.49% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for ATNM
The total capital return value is set at -64.79, while invested capital returns managed to touch -65.38. Equity return is now at value -34.50, with -32.20 for asset returns.
Based on Actinium Pharmaceuticals Inc. (ATNM), the company’s capital structure generated 1.20 points at debt to equity in total, while total debt to capital is 1.19. Total debt to assets is 1.11, with long-term debt to equity ratio resting at 0.51. Finally, the long-term debt to capital ratio is 0.50.
The liquidity ratio also appears to be rather interesting for investors as it stands at 13.62.